42nd Annual Miami Breast Cancer Conference® - Abstracts

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

ByClara Lam,Zakiya Haji-Noor,Simon Collin,Lisa Okazaki,Simone T. Sredni,Miriam Haviland,Angel Valladares,Caroline Tai,Joseph Imperato

May 31st 2025

41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists

ByClara Lam,Zakiya Haji-Noor,Simon Collin,Lisa Okazaki,Simone T. Sredni,Miriam Haviland,Joseph Imperato,Caroline Tai,Angel Valladares

May 30th 2025

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

ByAna Sandoval,Joyce A. O’Shaughnessy,Astra M. Liepa,Brenda Grimes,Katheryn Moreira,James Roose,Catherine Keane,Sara M. Tolaney, MD, MPH

May 29th 2025

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Rui Rui Zhang,Miguel Sampayo-Cordero,Juliana Carvalho-Santos,Olga Boix,Marta Beltran,Carlos Barrios,Guiseppe Curigliano,Rupert Bartsch,Anne Clair Hardy Bessard,Anna Compagnoni,Kathy Puyana Theall,Thomas Buechele,Tomer Wasserman,Javier Cortés, MD

May 28th 2025

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

ByHeather McArthur, MD, MPH,Rebecca Dent, MD,Rina Hui,Yeon Hee Park,Peter Schmid, MD,Jing Wei,Jaime Mejia,Wilbur Pan,Javier Cortés, MD

May 27th 2025

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

ByAnushree Iyengar,Sandhya Mehta,Hannah Barman,Nivedita Rangarajan,Sue-Ann Woo,Simone T. Sredni,Rosemarie Di Donato,Safak Simsek,Erinn P. Downs,Aziza Nassar,Darren M. Wilson,Katherine Krieser,Elise Bieri Patzke,Natalie Kyek,Jason Hipp,Tyler Wagner, PhD

May 25th 2025

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

ByKatheryn Moreira,Kathryn Hudson,Wambui Gathirua-Mwangi,Zhanglin Lin Cui,Madeline Richey,Brenda Grimes,Jingru Wang,Astra Liepa,Erich Brechtelsbauer,Raisa Volodarsky,Hatem Soliman, MD

May 24th 2025

52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

ByHarper Niver,Caroline Lippe,W. Bradford Carter

May 23rd 2025

53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

ByAreej Alhumaid,Alexandra Lopez-Aguiar,Kristin E. Rojas,Jessica Crystal,John Oeltjen,Devinder Singh,Susan B. Kesmodel

May 22nd 2025

54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

ByLinda Riks,Sophie Wooldrik,Taco Klem,Gerson Struik

May 21st 2025

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

ByNatalie Garver,Valerie L. Staradub, MD,Christopher Verdone,Kelly Mackessy,Alexandra Haraczy,Lianteng Zhi

May 20th 2025

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

ByErika King,Elisa Port,Borna Mohabbatizadeh,Christina Weltz,Jacquelyn Dillon,Jacquelyn Amenta,Mayuri Jain

May 19th 2025

57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers

ByFrances Phang,Anna Weiss, MD,Huina Zhang

May 18th 2025

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

ByLeslie Elmore,Neil Carleton,Michael S. Cowher,Rohit Bhargava,Emilia Diego,Kristin Lupinacci,Meaghan Marley,Qurat Ul Ain Sabih,Atilla Soran, MD, MPH,Jennifer Steiman,Ronald Johnson,Erin Bayley,Priscilla F. Mcauliffe, MD, PhD

May 17th 2025

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

ByMaria de la Torre,Erna Busch-Devereaux,Joyce Au

May 16th 2025

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

ByCamila Ortega,Micah Brainerd,Christopher Mamone,Caroline Mangira,Andrew Fenton,Mary Murray

May 15th 2025

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

BySheng Chow,Meredith Shamamian,Susan Laura Jao,Andreina Giron,Jessica Lin,Fardeen Bhimani,Eleni Kohilakis,Caroline Oska,Jana Fox,Sheldon Feldman,Maureen McEvoy

May 14th 2025

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

BySusan Laura Jao,Fardeen Bhimani,Arianna Cavalli,Bryan Harmon,Maureen McEvoy,Ethan Ravetch,Michelle Sheckley,Anjuli Gupta,Sheldon Feldman

May 13th 2025

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

ByAllen Gee,Grace Oh,June Lee

May 12th 2025

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

ByKen Weixing Ho,Nicholas Holford,Rathi Ramakrishnan,Patriek Jurrius,Sarah Pinder,Arnie Purushotham,Daniel Leff

May 11th 2025

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

ByArianna Cavalli,Susan Laura Jao,Skylar Harbour,Melissa Rony,Sheldon Feldman,Maureen McEvoy

May 10th 2025

70 Malignancy Upgrade Rates of Discordant Breast Lesions

ByJacquelyn Dillon,Carolyn Vanek,Jeanne Wu,Grace Van Hyfte,Victoria Collins,Christine Chen,Elisa Port,Jennifer L. Marti

May 9th 2025

71 Beyond the Surface: Suspicious Nipple Lesions

ByMargarita Riojas Barrett,Logan Healy,Neil Farnsworth,Elizabeth Bonefas,Alastair Thompson,Stacey Carter

May 8th 2025

72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes

ByHudhaifah Shaker,Kristin Manor,Shaneel Shah,Emma Barrett,Megan Bydder,Rajiv Dave,James C. Harvey, MD,Cliona Kirwan,Benjamin Baker

May 7th 2025

73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

ByHudhaifah Shaker,Eleanor Rees,Ian J Whitehead,Ansar Farooq,Noaman Sarfraz

May 6th 2025

74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

ByAnoushka Afonso,Joanna Serafin,Tiana Sepahpour,Tracy-Ann Moo,Hanae Tokita

May 5th 2025

75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial

ByFiras Eladoumikdachi,Deborah Toppmeyer, MD,Zeinab Abou Yehia,Nisha Ohri,Alison Grann,Maria Kowzun,Lindsay Potdevin,Shicha Kumar,Michele Blackwood,Bruce G. Haffty, MD

May 4th 2025

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

ByCarly Farrell,Nicole Harris,Paige Aiello,David Detz,Christine Laronga,Laura Kruper,Melissa Mallory,Susan Hoover,Nazanin Khakpour,John Kiluk,Weihong Sun,Junmin Whiting,Brian Czerniecki,Blaise Mooney,Marie Lee

May 3rd 2025